PCM
XERS icon

Pentwater Capital Management’s Xeris Biopharma Holdings XERS Stock Holding History

Pentwater Capital Management’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-40,000
Closed -$402K – 209
2019
Q1 		$402K Buy
+40,000
New +$513K 0.01% 127

Other funds holding XERS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Pentwater Capital Management's XERS Position: Q2 2019 in Review

Pentwater Capital Management sold out of Xeris Biopharma Holdings (XERS) in Q2 2019, closing a stake of 40,000 shares — an estimated $402K sold.

Pentwater Capital Management first reported a position in XERS in Q1 2019 and held it in 1 quarter. The position peaked at $402K in Q1 2019. 50 funds tracked by Wall St. Rank hold XERS as of Q2 2019.

  • Pentwater Capital Management reported no remaining Xeris Biopharma Holdings position as of Q2 2019 after selling out during the quarter.
  • Pentwater Capital Management sold 40,000 Xeris Biopharma Holdings shares in Q2 2019, an estimated $402K.
  • Pentwater Capital Management first reported a position in Xeris Biopharma Holdings in Q1 2019 and held it in 1 quarter.
  • Pentwater Capital Management's Xeris Biopharma Holdings position peaked at $402K in Q1 2019.
  • 50 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2019.

Based on Pentwater Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.